261 related articles for article (PubMed ID: 32207067)
41. The Role of IL-17 in the Pathogenesis of Psoriasis and Update on IL-17 Inhibitors for the Treatment of Plaque Psoriasis.
AbuHilal M; Walsh S; Shear N
J Cutan Med Surg; 2016 Nov; 20(6):509-516. PubMed ID: 27207350
[TBL] [Abstract][Full Text] [Related]
42. Risankizumab versus Ustekinumab for Moderate-to-Severe Plaque Psoriasis.
Papp KA; Blauvelt A; Bukhalo M; Gooderham M; Krueger JG; Lacour JP; Menter A; Philipp S; Sofen H; Tyring S; Berner BR; Visvanathan S; Pamulapati C; Bennett N; Flack M; Scholl P; Padula SJ
N Engl J Med; 2017 Apr; 376(16):1551-1560. PubMed ID: 28423301
[TBL] [Abstract][Full Text] [Related]
43. Brodalumab: A Review of Safety.
Rusta-Sallehy S; Gooderham M; Papp K
Skin Therapy Lett; 2018 Mar; 23(2):1-3. PubMed ID: 29562088
[TBL] [Abstract][Full Text] [Related]
44. Interleukin-17 receptor A blockade with brodalumab in palmoplantar pustular psoriasis: Report on four cases.
Pinter A; Wilsmann-Theis D; Peitsch WK; Mössner R
J Dermatol; 2019 May; 46(5):426-430. PubMed ID: 30786053
[TBL] [Abstract][Full Text] [Related]
45. Recapture Rate of Brodalumab in Patients With a Lapse in Treatment.
Lebwohl M; Cather J; Armstrong A; Van Voorhees A; Jacobson A
J Drugs Dermatol; 2020 Apr; 19(4):384-387. PubMed ID: 32272515
[TBL] [Abstract][Full Text] [Related]
46. A Case of Autoimmune Hepatitis during Brodalumab Treatment for Psoriasis.
Serizawa N; Hoashi T; Saeki H; Kanda N
J Nippon Med Sch; 2020; 87(6):359-361. PubMed ID: 33431762
[TBL] [Abstract][Full Text] [Related]
47. Dermatology Life Quality Index in Patients with Moderate-to-Severe Plaque Psoriasis Treated with Brodalumab or Ustekinumab.
Lambert J; Hansen JB; Sohrt A; Puig L
Dermatol Ther (Heidelb); 2021 Aug; 11(4):1265-1275. PubMed ID: 33988818
[TBL] [Abstract][Full Text] [Related]
48. Maintenance of clinical response and consistent safety profile with up to 3 years of continuous treatment with guselkumab: Results from the VOYAGE 1 and VOYAGE 2 trials.
Reich K; Griffiths CEM; Gordon KB; Papp KA; Song M; Randazzo B; Li S; Shen YK; Han C; Kimball AB; Armstrong AW; Foley P; Blauvelt A
J Am Acad Dermatol; 2020 Apr; 82(4):936-945. PubMed ID: 31809827
[TBL] [Abstract][Full Text] [Related]
49. The effect of bodyweight on the efficacy and safety of ixekizumab: results from an integrated database of three randomised, controlled Phase 3 studies of patients with moderate-to-severe plaque psoriasis.
Reich K; Puig L; Mallbris L; Zhang L; Osuntokun O; Leonardi C
J Eur Acad Dermatol Venereol; 2017 Jul; 31(7):1196-1207. PubMed ID: 28370467
[TBL] [Abstract][Full Text] [Related]
50. A 52-week, open-label study of the efficacy and safety of ixekizumab, an anti-interleukin-17A monoclonal antibody, in patients with chronic plaque psoriasis.
Gordon KB; Leonardi CL; Lebwohl M; Blauvelt A; Cameron GS; Braun D; Erickson J; Heffernan M
J Am Acad Dermatol; 2014 Dec; 71(6):1176-82. PubMed ID: 25242558
[TBL] [Abstract][Full Text] [Related]
51. Efficacy of Brodalumab and Guselkumab in Patients with Moderate-to-Severe Plaque Psoriasis Who are Inadequate Responders to Ustekinumab: A Matching Adjusted Indirect Comparison.
Hampton P; Borg E; Hansen JB; Augustin M
Psoriasis (Auckl); 2021; 11():123-131. PubMed ID: 34765537
[TBL] [Abstract][Full Text] [Related]
52. The comparative efficacy of brodalumab in patients with moderate-to-severe psoriasis: a systematic literature review and network meta-analysis.
Sawyer L; Fotheringham I; Wright E; Yasmeen N; Gibbons C; Holmen Møller A
J Dermatolog Treat; 2018 Sep; 29(6):557-568. PubMed ID: 29323542
[TBL] [Abstract][Full Text] [Related]
53. Safety of tildrakizumab for moderate-to-severe plaque psoriasis: pooled analysis of three randomized controlled trials.
Blauvelt A; Reich K; Papp KA; Kimball AB; Gooderham M; Tyring SK; Sinclair R; Thaçi D; Li Q; Cichanowitz N; Green S; La Rosa C
Br J Dermatol; 2018 Sep; 179(3):615-622. PubMed ID: 29742274
[TBL] [Abstract][Full Text] [Related]
54. Users of biologics in clinical practice: would they be eligible for phase III clinical studies? Cohort Study in the French Psoriasis Registry PSOBIOTEQ.
Masson Regnault M; Castañeda-Sanabria J; Diep Tran MHT; Beylot-Barry M; Bachelez H; Beneton N; Chosidow O; Dupuy A; Joly P; Jullien D; Mahé E; Richard MA; Viguier M; Tubach F; Sbidian E; Paul C;
J Eur Acad Dermatol Venereol; 2020 Feb; 34(2):293-300. PubMed ID: 31419355
[TBL] [Abstract][Full Text] [Related]
55. Infections from seven clinical trials of ixekizumab, an anti-interleukin-17A monoclonal antibody, in patients with moderate-to-severe psoriasis.
Papp KA; Bachelez H; Blauvelt A; Winthrop KL; Romiti R; Ohtsuki M; Acharya N; Braun DK; Mallbris L; Zhao F; Xu W; Walls CD; Strober B
Br J Dermatol; 2017 Dec; 177(6):1537-1551. PubMed ID: 28600810
[TBL] [Abstract][Full Text] [Related]
56. Three-year U.S. pharmacovigilance report of brodalumab.
Lebwohl M; Leonardi C; Armstrong A; Rawnsley N; Alexander B; Goehring E; Kerdel F; Jacobson A
Dermatol Ther; 2021 Nov; 34(6):e15105. PubMed ID: 34418244
[TBL] [Abstract][Full Text] [Related]
57. Secukinumab long-term safety experience: A pooled analysis of 10 phase II and III clinical studies in patients with moderate to severe plaque psoriasis.
van de Kerkhof PC; Griffiths CE; Reich K; Leonardi CL; Blauvelt A; Tsai TF; Gong Y; Huang J; Papavassilis C; Fox T
J Am Acad Dermatol; 2016 Jul; 75(1):83-98.e4. PubMed ID: 27180926
[TBL] [Abstract][Full Text] [Related]
58. A phase 4, randomized, head-to-head trial comparing the efficacy of subcutaneous injections of brodalumab to oral administrations of fumaric acid esters in adults with moderate-to-severe plaque psoriasis (CHANGE).
Pinter A; Hoffmann M; Reich K; Augustin M; Kaplan K; Gudjónsdóttir SD; Delvin T; Mrowietz U;
J Eur Acad Dermatol Venereol; 2021 Mar; 35(3):701-711. PubMed ID: 32939860
[TBL] [Abstract][Full Text] [Related]
59. Brodalumab to the Rescue: Efficacy and Safety of Brodalumab in Patients with Psoriasis and Prior Exposure or Inadequate Response to Biologics.
Menter A; Armstrong A; Van Voorhees A; Liu C; Jacobson A
Dermatol Ther (Heidelb); 2020 Aug; 10(4):615-621. PubMed ID: 32533554
[TBL] [Abstract][Full Text] [Related]
60. Long-term efficacy of novel therapies in moderate-to-severe plaque psoriasis: a systematic review and network meta-analysis of PASI response.
Sawyer LM; Cornic L; Levin LÅ; Gibbons C; Møller AH; Jemec GB
J Eur Acad Dermatol Venereol; 2019 Feb; 33(2):355-366. PubMed ID: 30289198
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
